Antiviral activity of lanatoside C against dengue virus infection
Autor(es): Cheung Yan Yi, Chen Karen Caiyun, Chen Huixin, Seng Eng Khuan, Chu Justin Jang Hann
Resumo: Dengue infection poses a serious threat globally due to its recent rapid spread - rise in incidence. Currently, there is no approved vaccine or effective antiviral drug for dengue virus infection. In response to the urgent need for the development of an effective antiviral for dengue virus, the US Drug Collection library was screened in this study to identify compounds with anti-dengue activities. Lanatoside C, an FDA approved cardiac glycoside was identified as a c-idate anti-dengue compound. Our data revealed that lanatoside C has an IC50 of 0.19?M for dengue virus infection in HuH-7 cells. Dose-dependent reduction in dengue viral RNA - viral proteins synthesis were also observed upon treatment with increasing concentrations of lanatoside C. Time of addition study indicated that lanatoside C inhibits the early processes of the dengue virus replication cycle. Furthermore, lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya - Sindbis virus as well as the human enterovirus 71. These findings suggest that lanatoside C possesses broad spectrum antiviral activity against several groups of positive-sense RNA viruses.
Palavras-Chave: Antiviral compounds; Cardiac glycoside; Dengue virus; Flavivirus; Lanatoside C
Imprenta: Antiviral Research, v. 111, p. 93-99, 2014
Identificador do objeto digital: 10.1016/j.antiviral.2014.09.007
Descritores: Chikungunya virus - Cell ; Chikungunya virus - Flaviviridae ; Chikungunya virus - Pathogenesis ; Chikungunya virus - Proteins ; Chikungunya virus - RNA ; Chikungunya virus - Viral infections ; Chikungunya Virus - Virus ; Chikungunya virus - Vaccine ; Chikungunya virus - Dengue
Data de publicação: 2014
